IN BRIEF: Hutchison China starts first phase trials for HMPL-306
IN BRIEF: Hutchison China starts first phase trials for HMPL-306
Read moreThu, 18th Jun 2020 09:18
IN BRIEF: Hutchison China starts first phase trials for HMPL-306
Read moreTRADING UPDATES: Arden Partners to return to annual profitability
Read moreTRADING UPDATES: Origin Enterprises loss slims; Amryt issues guidance
Read moreUK Earnings, Trading Statements Calendar - Next 7 Days
Read moreUK TRADING UPDATE SUMMARY: Science Group To Beat Forecasts For 2020
Read moreIN BRIEF: Hutchison China Lands "Milestone" China Drug Green Light
Read moreHutchison China Files US FDA Drug Application For Cancer Treatment
Read moreIN BRIEF: Hutchison Chi-Med To Issue USD100 Million In Shares To CPP
Read moreUK TRADING UPDATE SUMMARY: Hutchison China Drug Application Accepted
Read more(Sharecast News) - Hutchison China MediTech, trading as Chi-Med, said on Friday that it has initiated 'FRESCO-2' - a phase 3 registration study of 'fruquintinib' for the treatment of patients with metastatic colorectal cancer (CRC) in the US, Europe and Japan.
Read moreIN BRIEF: Hutchison China Initiates Phase II Trial Of HMPL-453
Read moreIN BRIEF: Hutchison Chi-Med Plans Surufatnib Marketing Application
Read moreIN BRIEF: Hutchison China Interim Loss Widens Despite Revenue Growth
Read moreIN BRIEF: Hutchison China Amends License Agreement With Eli Lilly
Read more(Sharecast News) - Hutchison China MediTech, trading as Chi-Med, has initiated a phase 1 study of 'HMPL-306', it announced on Friday, in patients with hematological malignancies in China.
Read more